-+ 0.00%
-+ 0.00%
-+ 0.00%

Crescent Biopharma Q3 net loss widens 53% to $37.73 million

PUBT·11/12/2026 21:33:01
Listen to the news
Crescent Biopharma Q3 net loss widens 53% to $37.73 million
  • Crescent Biopharma’s third-quarter 2026 net loss widened 53% year over year to $37.73 million.
  • Research and development expenses rose 69% to $34.31 million, supporting increased ASCEND clinical development and preparations for APOLLO’s initiation.
  • Cash and cash equivalents totaled $289.4 million at September 30, expected to fund operations into the second half of 2028.
  • Initial CR-001 monotherapy data remain on track for the first quarter of 2027; patient dosing began in CR-002’s global APOLLO trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121615PRIMZONEFULLFEED9876807) on November 12, 2026, and is solely responsible for the information contained therein.